将肿瘤坏死因子α作为一种增强黑色素瘤中CD8 T细胞依赖性免疫反应的新策略？
Targeting TNF alpha as a novel strategy to enhance CD8 T cell-dependent immune response in melanoma?
作者信息
Bertrand Florie, Rochotte Julia, Colacios Céline, Montfort Anne, Andrieu-Abadie Nathalie, Levade Thierry, Benoist Hervé, Ségui Bruno
机构信息
INSERM UMR 1037, CRCT, Toulouse, France; Equipe Labellisée Ligue Contre Le Cancer, Toulouse, France.
INSERM UMR 1037, CRCT, Toulouse, France; Equipe Labellisée Ligue Contre Le Cancer, Toulouse, France; Université Toulouse III - Paul Sabatier, Toulouse, France.
出版信息
Oncoimmunology. 2015 Aug 12;5(1):e1068495. doi: 10.1080/2162402X.2015.1068495. eCollection 2016.
Abstract
Tumor Necrosis Factor α (TNF) is a pleiotropic cytokine exhibiting a dual activity in oncoimmunology, either acting as a cytotoxic effector produced by leukocytes or behaving as an immunosuppressive molecule. We have just discovered that TNF signaling impairs the accumulation of tumor-infiltrating CD8 T lymphocytes in experimental melanoma.
摘要
肿瘤坏死因子α（TNF）是一种多效性细胞因子，在肿瘤免疫中表现出双重活性，既可以作为白细胞产生的细胞毒性效应因子，也可以作为一种免疫抑制分子。我们刚刚发现，在实验性黑色素瘤中，TNF信号传导会损害肿瘤浸润性CD8 T淋巴细胞的积累。
相似文献
1
Targeting TNF alpha as a novel strategy to enhance CD8 T cell-dependent immune response in melanoma?
Oncoimmunology. 2015 Aug 12;5(1):e1068495. doi: 10.1080/2162402X.2015.1068495. eCollection 2016.
2
Blocking Tumor Necrosis Factor α Enhances CD8 T-cell-Dependent Immunity in Experimental Melanoma.
Cancer Res. 2015 Jul 1;75(13):2619-28. doi: 10.1158/0008-5472.CAN-14-2524. Epub 2015 May 14.
3
Engineered CD8+ cytotoxic T cells with fiber-modified adenovirus-mediated TNF-alpha gene transfection counteract immunosuppressive interleukin-10-secreting lung metastasis and solid tumors.
Cancer Gene Ther. 2007 Jul;14(7):661-75. doi: 10.1038/sj.cgt.7701039. Epub 2007 May 4.
4
The Significance of Tumor Necrosis Factor Receptor Type II in CD8 Regulatory T Cells and CD8 Effector T Cells.
Front Immunol. 2018 Mar 22;9:583. doi: 10.3389/fimmu.2018.00583. eCollection 2018.
5
Multiple sub-sets of CD4+ and CD8+ cytotoxic T-cell clones directed to autologous human melanoma identified by cytokine profiles.
Int J Cancer. 1994 Apr 1;57(1):56-62. doi: 10.1002/ijc.2910570111.
6
TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma.
Nat Commun. 2017 Dec 22;8(1):2256. doi: 10.1038/s41467-017-02358-7.
7
Targeting Tumor Vasculature with TNF Leads Effector T Cells to the Tumor and Enhances Therapeutic Efficacy of Immune Checkpoint Blockers in Combination with Adoptive Cell Therapy.
Clin Cancer Res. 2018 May 1;24(9):2171-2181. doi: 10.1158/1078-0432.CCR-17-2210. Epub 2018 Feb 28.
8
A role for TNF in limiting the duration of CTL effector phase and magnitude of CD8 T cell memory.
J Leukoc Biol. 2007 Nov;82(5):1201-11. doi: 10.1189/jlb.0407240. Epub 2007 Aug 17.
9
Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1-binding melanoma and viral peptide antigens.
J Immunol Methods. 1996 May 27;191(2):131-42. doi: 10.1016/0022-1759(96)00007-5.
10
Characterization of autologous tumor-specific T-helper 2 cells in tumor-infiltrating lymphocytes from a patient with metastatic melanoma.
Int J Cancer. 1994 Aug 1;58(3):317-23. doi: 10.1002/ijc.2910580302.
引用本文的文献
1
Programmed Cell Death Protein 1 Contributes to Oral Cancer Pain via Regulating Tumor Necrosis Factor Alpha in the Spinal Trigeminal Nucleus Caudalis.
Curr Neuropharmacol. 2025;23(5):594-601. doi: 10.2174/1570159X23666241209160039.
2
Inhibition of insulin-like growth factors increases production of CXCL9/10 by macrophages and fibroblasts and facilitates CD8 cytotoxic T cell recruitment to pancreatic tumours.
Front Immunol. 2024 Aug 5;15:1382538. doi: 10.3389/fimmu.2024.1382538. eCollection 2024.
3
Coagulation Protease-Driven Cancer Immune Evasion: Potential Targets for Cancer Immunotherapy.
Cancers (Basel). 2024 Apr 19;16(8):1568. doi: 10.3390/cancers16081568.
4
Generation of Cytotoxic T Cells and Dysfunctional CD8 T Cells in Severe COVID-19 Patients.
Cells. 2022 Oct 25;11(21):3359. doi: 10.3390/cells11213359.
5
Cationic Polyethyleneimine (PEI)-Gold Nanocomposites Modulate Macrophage Activation and Reprogram Mouse Breast Triple-Negative MET-1 Tumor Immunological Microenvironment.
Pharmaceutics. 2022 Oct 19;14(10):2234. doi: 10.3390/pharmaceutics14102234.
6
Acetone Extract of Leaves Exerts Anti-Melanoma Effects via Inhibiting STAT3 Signaling.
Onco Targets Ther. 2021 May 28;14:3487-3501. doi: 10.2147/OTT.S308371. eCollection 2021.
7
High Endothelial Venule with Concomitant High CD8+ Tumor-Infiltrating Lymphocytes Is Associated with a Favorable Prognosis in Resected Gastric Cancer.
J Clin Med. 2020 Aug 13;9(8):2628. doi: 10.3390/jcm9082628.
8
Effects of the IL6 -174G>C promoter polymorphism and IL-6 serum levels on the progression of cutaneous malignant melanoma.
Oncol Lett. 2020 Aug;20(2):1781-1791. doi: 10.3892/ol.2020.11740. Epub 2020 Jun 16.
9
TNF-α in T lymphocytes attenuates renal injury and fibrosis during nephrotoxic nephritis.
Am J Physiol Renal Physiol. 2020 Jan 1;318(1):F107-F116. doi: 10.1152/ajprenal.00347.2019. Epub 2019 Nov 18.
10
Investigating Macrophages Plasticity Following Tumour-Immune Interactions During Oncolytic Therapies.
Acta Biotheor. 2019 Dec;67(4):321-359. doi: 10.1007/s10441-019-09357-9. Epub 2019 Aug 13.
本文引用的文献
1
Blocking Tumor Necrosis Factor α Enhances CD8 T-cell-Dependent Immunity in Experimental Melanoma.
Cancer Res. 2015 Jul 1;75(13):2619-28. doi: 10.1158/0008-5472.CAN-14-2524. Epub 2015 May 14.
2
Phenotype and function of T cells infiltrating visceral metastases from gastrointestinal cancers and melanoma: implications for adoptive cell transfer therapy.
J Immunol. 2013 Sep 1;191(5):2217-25. doi: 10.4049/jimmunol.1300538. Epub 2013 Jul 31.
3
High endothelial venules (HEVs) in human melanoma lesions: Major gateways for tumor-infiltrating lymphocytes.
Oncoimmunology. 2012 Sep 1;1(6):829-839. doi: 10.4161/onci.20492.
4
TNF signaling drives myeloid-derived suppressor cell accumulation.
J Clin Invest. 2012 Nov;122(11):4094-104. doi: 10.1172/JCI64115. Epub 2012 Oct 15.
5
Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation.
Nature. 2012 Oct 18;490(7420):412-6. doi: 10.1038/nature11538. Epub 2012 Oct 10.
6
Tumor high endothelial venules (HEVs) predict lymphocyte infiltration and favorable prognosis in breast cancer.
Oncoimmunology. 2012 Aug 1;1(5):789-790. doi: 10.4161/onci.19787.
7
BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency.
Clin Cancer Res. 2012 Apr 15;18(8):2326-35. doi: 10.1158/1078-0432.CCR-11-2515. Epub 2012 Feb 21.
8
A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer.
Ann Oncol. 2008 Jul;19(7):1340-1346. doi: 10.1093/annonc/mdn054. Epub 2008 Mar 5.
9
Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+CD25+ T regulatory cells.
J Immunol. 2007 Jul 1;179(1):154-61. doi: 10.4049/jimmunol.179.1.154.
10
Induction of apoptosis in mature T cells by tumour necrosis factor.
Nature. 1995 Sep 28;377(6547):348-51. doi: 10.1038/377348a0.
Zotero 插件